Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class (Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists, Phosphodiesterase 5), And Segment Forecasts, 2020 - 2027

Published by Grand View Research, Inc. Product code 408939
Published Content info 112 Pages
Delivery time: 2-3 business days
Price
Back to Top
Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class (Prostacyclin & Prostacyclin Analogs, Endothelin Receptor Antagonists, Phosphodiesterase 5), And Segment Forecasts, 2020 - 2027
Published: February 17, 2020 Content info: 112 Pages
Description

The global pulmonary arterial hypertension market size is expected to reach USD 9.8 billion by 2027, according to a new report by Grand View Research, Inc., registering a CAGR of 5.6% over the forecast period. Increasing prevalence rates of pulmonary arterial hypertension (PAH) and government support for the development of orphan drugs drive the market growth.

The cases of PAH are rising in the range of 100,000 to 200,000 per year. However, in the past few years, the occurrence of PAH has been increasing due to risk factors such as alcohol/tobacco consumption, HIV, sedentary lifestyle, smoking, and other idiopathic conditions. Moreover, the geriatric population is more prone to PAH and associated diseases owing to reduced immune function. According to the National Council on Aging (NCOA), about 80 percent of the population aged 65 and above have at least one chronic condition such as high cholesterol, diabetes, heart or kidney disease, or chronic obstructive pulmonary disease.

Government initiatives such as the Rare Disease Act 2002 and The Orphan Drug Act (ODA) 1983, are also anticipated to support the market for treatment drugs for PAH. These acts play a significant role in promoting the ethical usage and distribution of orphan drugs. The development of orphan drugs is promoted by the National Organization of Rare Disorders.

Robust drug pipeline and new product combinations awaiting approval or launch are anticipated to increase the PAH market competitiveness over the forecast period. In September 2019, Acceleron Pharma, a leading biopharmaceutical company, received FDA orphan drug designation for sotatercept for the treatment of pulmonary arterial hypertension.

Further key findings from the report suggest:

Prostacyclin and its analogs for treating PAH are projected to show lucrative growth over the forecast period. The sales of these drugs are anticipated to increase due to the growing use of oral prostacyclin agents

North America dominated the PAH market with a share of over 55.0% in 2019. This is attributed to the well-established infrastructure for the development and distribution of high-quality therapies and the availability of reimbursement for PAH therapies

Asia Pacific is estimated to register the highest CAGR of more than 6.0% over the forecast period due to its huge population base, rapid economic development, and improving healthcare system. Moreover, the high burden of diseases such as HIV in the region contribute to the development of PAH

The major players in the pulmonary arterial hypertension market that offer treatment solutions for PAH include GlaxoSmithKline plc; Johnson & Johnson Services, Inc. (Actelion Pharmaceuticals, Ltd.); United Therapeutics Corporation; Pfizer, Inc.; and Gilead Sciences, Inc. The market is consolidated and competitive in nature. The players enjoy the benefit of high entry barriers to other firms due to high price interdependency

Table of Contents
Product Code: GVR-2-68038-855-8

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Drug
    • 1.1.2 Regional Scope
    • 1.1.3 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 Gvr's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
      • 1.6.1.1 Approach 1: Commodity Flow Approach
    • 1.6.2 Volume Price Analysis (Model 2)
      • 1.6.2.1 Approach 2: Volume Price Analysis
  • 1.7 List of Secondary Sources
  • 1.8 List of Primary Sources
  • 1.9 List of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective - 1:
    • 1.10.2 Objective - 2:
    • 1.10.3 Objective - 3:
    • 1.10.4 Objective - 4:

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook
  • 2.3 Business Segment Trends
    • 2.3.1 Service Business Analysis
    • 2.3.2 Application Business Analysis
    • 2.3.3 Regional Business Analysis
  • 2.4 Competitive Insights

Chapter 3 Pulmonary Arterial Hypertension Market: Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market Outlook
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Product Pipeline Analysis, By Stage
    • 3.3.1 Registration Phase
  • 3.4 User Perspective Analysis
    • 3.4.1 Consumer Behavior Analysis
    • 3.4.2 Market Influencer Analysis
  • 3.5 List Of Key End-Users, By Region / By Product / By Country
  • 3.6 Regulatory Framework
    • 3.6.1 Reimbursement Framework
      • 3.6.1.1 Therapy Cost
      • 3.6.1.2 Therapy Monitoring Cost
      • 3.6.1.3 Average Selling Price
    • 3.6.2 Standards & Compliances
  • 3.7 Market Variable Analysis
    • 3.7.1 Market Driver Analysis
      • 3.7.1.1 Incidents Of Pulmonary Arterial Hypertension (PAH)
      • 3.7.1.2 Growing Geriatric Population
      • 3.7.1.3 Government Support For Development Of Orphan Drugs
    • 3.7.2 Market Restraint Analysis
      • 3.7.2.1 Patent Expiration Of Key Molecules
    • 3.7.3 Industry Challenges
  • 3.8 Pulmonary Arterial Hypertension Market: Analysis Tools
    • 3.8.1 Porter's Five Forces Analysis
      • 3.8.1.1 Supplier Power: Low
      • 3.8.1.2 Buyer Power: Moderate
      • 3.8.1.3 Substitution Threat: Moderate
      • 3.8.1.4 Threat From New Entrant: Moderate
      • 3.8.1.5 Competitive Rivalry: High
    • 3.8.2 Pestel Analysis
    • 3.8.3 Major Deals & Strategic Alliances Analysis
    • 3.8.4 Market Entry Strategies

Chapter 4 Pulmonary Arterial Hypertension Market: Drug Class Segment Analysis

  • 4.1 Pulmonary Arterial Hypertension Market: Definition & Scope
  • 4.2 Pulmonary Arterial Hypertension: Market Share Analysis, 2019 & 2027
  • 4.3 Prostacyclin and Prostacyclin Analogs
    • 4.3.1 Prostacyclin and Prostacyclin Analogs market, 2016 - 2027 (USD Million)
  • 4.4 Soluble Guanylate Cyclase (SGC) Stimulators
    • 4.4.1 Soluble Guanylate Cyclase (SGC) Stimulators market, 2016 - 2027 (USD Million)
  • 4.5 Endothelin Receptor Antagonists (ERAs)
    • 4.5.1 Endothelin Receptor Antagonists (ERAS) market, 2016 - 2027 (USD Million)
  • 4.6 Phosphodiesterase 5 (PDE-5)
    • 4.6.1 Phosphodiesterase 5 (PDE-5) market, 2016 - 2027 (USD Million)

Chapter 5 Pulmonary Arterial Hypertension Market: Regional Analysis

  • 5.1 Pulmonary Arterial Hypertension Market: Definition & Scope
  • 5.2 Regional Market Snapshot
  • 5.3 Regional Market Share and Leading Players, 2018
    • 5.3.1 North America
    • 5.3.2 Europe
    • 5.3.3 Asia Pacific
    • 5.3.4 Latin America
    • 5.3.5 Middle East & Africa
  • 5.4 Pulmonary Arterial Hypertension Market: Market Share Analysis, 2018 & 2027
  • 5.5 North America
    • 5.5.1 North America Pulmonary Arterial Hypertension market, 2016 - 2027 (USD Million)
    • 5.5.2 U.S.
      • 5.5.2.1 U.S. Pulmonary Arterial Hypertension market, 2016 - 2027 (USD Million)
    • 5.5.3 Canada
      • 5.5.3.1 Canada Pulmonary Arterial Hypertension market, 2016 - 2027 (USD Million)
  • 5.6 Europe
    • 5.6.1 Europe Pulmonary Arterial Hypertension market, 2016 - 2027 (USD Million)
    • 5.6.2 U.K.
      • 5.6.2.1 U.K. Pulmonary Arterial Hypertension market, 2016 - 2027 (USD Million)
    • 5.6.3 Germany
      • 5.6.3.1 Germany Pulmonary Arterial Hypertension market, 2016 - 2027 (USD Million)
    • 5.6.4 France
      • 5.6.4.1 France Pulmonary Arterial Hypertension market, 2016 - 2027 (USD Million)
    • 5.6.5 Italy
      • 5.6.5.1 Italy Pulmonary Arterial Hypertension market, 2016 - 2027 (USD Million)
    • 5.6.6 Spain
      • 5.6.6.1 Spain Pulmonary Arterial Hypertension market, 2016 - 2027 (USD Million)
  • 5.7 Asia Pacific
    • 5.7.1 Asia Pacific Pulmonary Arterial Hypertension market, 2016 - 2027 (USD Million)
    • 5.7.2 Japan
      • 5.7.2.1 Japan Pulmonary Arterial Hypertension market, 2016 - 2027 (USD Million)
    • 5.7.3 China
      • 5.7.3.1 China Pulmonary Arterial Hypertension market, 2016 - 2027 (USD Million)
    • 5.7.4 Australia
      • 5.7.4.1 Australia Pulmonary Arterial Hypertension market, 2016 - 2027 (USD Million)
    • 5.7.5 South Korea
      • 5.7.5.1 South Korea Pulmonary Arterial Hypertension market, 2016 - 2027 (USD Million)
    • 5.7.6 India
      • 5.7.6.1 India Pulmonary Arterial Hypertension market, 2016 - 2027 (USD Million)
  • 5.8 Latin America
    • 5.8.1 Latin America Pulmonary Arterial Hypertension market, 2016 - 2027 (USD Million)
    • 5.8.2 Brazil
      • 5.8.2.1 Brazil Pulmonary Arterial Hypertension market, 2016 - 2027 (USD Million)
    • 5.8.3 Mexico
      • 5.8.3.1 Mexico Pulmonary Arterial Hypertension market, 2016 - 2027 (USD Million)
    • 5.8.4 Argentina
      • 5.8.4.1 Argentina Pulmonary Arterial Hypertension market, 2016 - 2027 (USD Million)
  • 5.9 MEA
    • 5.9.1 MEA Pulmonary Arterial Hypertension market, 2016 - 2027 (USD Million)
    • 5.9.2 South Africa
      • 5.9.2.1 South Africa Pulmonary Arterial Hypertension market, 2016 - 2027 (USD Million)
    • 5.9.3 Saudi Arabia.
      • 5.9.3.1 Saudi Arabia Pulmonary Arterial Hypertension market, 2016 - 2027 (USD Million)
    • 5.9.4 UAE
      • 5.9.4.1 UAE Pulmonary Arterial Hypertension market, 2016 - 2027 (USD Million)

Chapter 6 Company Profiles

  • 6.1 Company Profiles
    • 6.1.1 Johnson & Johnson Services, Inc. (Actelion Pharmaceuticals, Ltd.)
      • 6.1.1.1 Company overview
      • 6.1.1.2 Financial performance
      • 6.1.1.3 Product benchmarking
      • 6.1.1.4 Strategic initiatives
    • 6.1.2 Gilead Sciences, Inc.
      • 6.1.2.1 Company overview
      • 6.1.2.2 Financial Performance
      • 6.1.2.3 Product benchmarking
      • 6.1.2.4 Strategic initiatives
    • 6.1.3 United Therapeutics Corporation
      • 6.1.3.1 Company overview
      • 6.1.3.2 Financial performance
      • 6.1.3.3 PAH Global Sale
      • 6.1.3.4 Product benchmarking
      • 6.1.3.5 Strategic initiatives
    • 6.1.4 Novartis International AG
      • 6.1.4.1 Company overview
      • 6.1.4.2 Financial Performance
      • 6.1.4.3 Product benchmarking
      • 6.1.4.4 Strategic initiatives
    • 6.1.5 GlaxoSmithKline Plc. (GSK)
      • 6.1.5.1 Company overview
      • 6.1.5.2 Financial performance
      • 6.1.5.3 Product benchmarking
    • 6.1.6 Pfizer, Inc.
      • 6.1.6.1 Company overview
      • 6.1.6.2 Product benchmarking
    • 6.1.7 Dong-A ST Co., Ltd.
      • 6.1.7.1 Company overview
      • 6.1.7.2 Financial performance
      • 6.1.7.3 Product benchmarking
      • 6.1.7.4 Strategic initiatives
    • 6.1.8 Merck Sharp & Dohme Corp.
      • 6.1.8.1 Company overview
      • 6.1.8.2 Financial Performance
      • 6.1.8.3 Product benchmarking
      • 6.1.8.4 Strategic initiatives
    • 6.1.9 Bayer HealthCare
      • 6.1.9.1 Company overview
      • 6.1.9.2 Financial Performance
      • 6.1.9.3 Product benchmarking
      • 6.1.9.4 Strategic initiatives
    • 6.1.10 Arena Pharmaceuticals
      • 6.1.10.1 Company overview
      • 6.1.10.2 Financial performance
      • 6.1.10.3 Product benchmarking

Chapter 7 KOL Commentary

  • 7.1 Key Insights
  • 7.2 KOL Views

Chapter 8 Recommendations

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Product pipeline analysis
  • Table 4 Pipeline Analysis for the PAH Agents
  • Table 5 Monthly therapy cost for PAH agents
  • Table 6 Payer specific per patient per year monitoring cost by medication class
  • Table 7 Average selling prices for approved PAH agents in the U.S.
  • Table 8 Global Pulmonary Arterial Hypertension Market, by Region, 2016 - 2027 (USD Million)
  • Table 9 Global Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 10 North America Pulmonary Arterial Hypertension Market, by Region, 2016 - 2027 (USD Million)
  • Table 11 North America Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 12 U.S. Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 13 Canada Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 14 Europe Pulmonary Arterial Hypertension Market, by Region, 2016 - 2027 (USD Million)
  • Table 15 Europe Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 16 U.K. Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 17 Germany Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 18 Spain Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 19 Italy Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 20 France Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 21 RoE Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 22 Asia Pacific Pulmonary Arterial Hypertension Market, by Region, 2016 - 2027 (USD Million)
  • Table 23 Asia Pacific Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 24 Japan Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 25 China Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 26 India Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 27 Australia Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 28 South Korea Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 29 RoAPAC Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 30 Latin America Pulmonary Arterial Hypertension Market, by Region, 2016 - 2027 (USD Million)
  • Table 31 Latin America Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 32 Brazil Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 33 Mexico Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 34 Argentina Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 35 RoLA Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 36 MEA Pulmonary Arterial Hypertension Market, by Region, 2016 - 2027 (USD Million)
  • Table 37 MEA Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 38 South Africa Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 39 Saudi Arabia Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 40 UAE Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)
  • Table 41 RoMEA Pulmonary Arterial Hypertension Market, by Drug Class, 2016 - 2027 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Commodity Flow Analysis
  • Fig. 9 Volume Price Analysis
  • Fig. 10 Pulmonary arterial hypertension market snapshot (2019)
  • Fig. 11 Pulmonary arterial hypertension market segmentation
  • Fig. 12 Pulmonary arterial hypertension market: Strategy framework
  • Fig. 13 Market trends and outlook
  • Fig. 14 Parent market outlook
  • Fig. 15 Related/ancillary market outlook
  • Fig. 16 Penetration & growth prospect mapping
  • Fig. 17 Market driver relevance analysis (Current & future impact)
  • Fig. 18 Global prevalence of PAH
  • Fig. 19 Global geriatric population, 2014 - 2024 (Million)
  • Fig. 20 Market restraint relevance analysis (Current & future impact)
  • Fig. 21 Patent term expiry of the key PAH brand
  • Fig. 22 Porter's Five Forces analysis
  • Fig. 23 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 24 Pulmonary arterial hypertension market drug class outlook: Segment dashboard
  • Fig. 25 Pulmonary arterial hypertension market: Drug class movement analysis
  • Fig. 26 Prostacyclin pathway
  • Fig. 27 Prostacyclin and prostacyclin analogs market, 2016 - 2027 (USD Million)
  • Fig. 28 Nitric oxide pathway
  • Fig. 29 Soluble guanylate cyclase (SGC) stimulators market, 2016 - 2027 (USD Million)
  • Fig. 30 Endothelial pathway
  • Fig. 31 Endothelin receptor antagonists (ERA) market, 2016 - 2027 (USD Million)
  • Fig. 32 Nitric oxide pathway market, 2016 - 2027 (USD Million)
  • Fig. 33 Phosphodiesterase 5 (PDE-5) market, 2016 - 2027 (USD Million)
  • Fig. 34 Regional market place: Key takeaways
  • Fig. 35 Pulmonary Arterial Hypertension Market: Definition & Scope
  • Fig. 36 Regional Market Snapshot (Figures in USD Million, 2019)
  • Fig. 37 Regional Market Share, 2019 (USD Million)
  • Fig. 38 Regional outlook, 2019 & 2027
  • Fig. 39 North America market, 2016 - 2027 (USD Million)
  • Fig. 40 U.S. market, 2016 - 2027 (USD Million)
  • Fig. 41 Canada market, 2016 - 2027 (USD Million)
  • Fig. 42 Europe market, 2016 - 2027 (USD Million)
  • Fig. 43 U.K. market, 2016 - 2027 (USD Million)
  • Fig. 44 Germany market, 2016 - 2027 (USD Million)
  • Fig. 45 France market, 2016 - 2027 (USD Million)
  • Fig. 46 Italy market, 2016 - 2027 (USD Million)
  • Fig. 47 Spain market, 2016 - 2027 (USD Million)
  • Fig. 48 Asia Pacific market, 2016 - 2027 (USD Million)
  • Fig. 49 Japan market, 2016 - 2027 (USD Million)
  • Fig. 50 China market, 2016 - 2027 (USD Million)
  • Fig. 51 India market, 2016 - 2027 (USD Million)
  • Fig. 52 Australia market, 2016 - 2027 (USD Million)
  • Fig. 53 South Korea market, 2016 - 2027 (USD Million)
  • Fig. 54 Latin America market, 2016 - 2027 (USD Million)
  • Fig. 55 Brazil market, 2016 - 2027 (USD Million)
  • Fig. 56 Mexico market, 2016 - 2027 (USD Million)
  • Fig. 57 Argentina market, 2016 - 2027 (USD Million)
  • Fig. 58 MEA market, 2016 - 2027 (USD Million)
  • Fig. 59 South Africa market, 2016 - 2027 (USD Million)
  • Fig. 60 Saudi Arabia market, 2016 - 2027 (USD Million)
  • Fig. 61 UAE market, 2016 - 2027 (USD Million)
Back to Top